Stock Events

Stock Events

MindBio Therapeutics 

€0.7
0
+€0.01+1.75% Wednesday 07:55

Statistics

Day High
0.7
Day Low
0.7
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2022
2023
2024
0Revenue
-1.6MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow WF60.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap606.35M
Compass Pathways focuses on psilocybin therapy for depression, directly competing in the psychedelic-assisted therapy space.
AtaiBeckley
ATAI
Mkt Cap1.56B
ATAI Life Sciences works on mental health treatments using psychedelics and other compounds, overlapping with MindBio's therapeutic areas.
GH Research
GHRS
Mkt Cap888.26M
GH Research focuses on developing 5-MeO-DMT therapies for depression, a direct competitor in psychedelic research for mental health.
Revive Therapeutics
RVVTF
Mkt Cap4.68M
Revive Therapeutics explores psilocybin for the treatment of various ailments, including mental health disorders, competing with MindBio.
Red Light Holland
TRIP.CN
Mkt Cap47.58M
Red Light Holland produces and sells truffles to the legal, recreational market but is moving towards therapeutic uses, indirectly competing.

About

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.
Show more...
CEO
Mr. Justin Adam Hanka
Country
DE
ISIN
CA60256C2076
WKN
000A41RJS

Listings

F
DE
WF60.F
CN
CA
MBIO.CN
OTC Link
US
MBQIF

0 Comments

Share your thoughts

FAQ

What is MindBio Therapeutics stock price today?▼
The current price of WF60.F is €0.7 EUR — it has increased by +1.75% in the past 24 hours. Watch MindBio Therapeutics stock price performance more closely on the chart.
What is MindBio Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MindBio Therapeutics stocks are traded under the ticker WF60.F.
What is MindBio Therapeutics revenue for the last year?▼
MindBio Therapeutics revenue for the last year amounts to 0 EUR.
What is MindBio Therapeutics net income for the last year?▼
WF60.F net income for the last year is -1.6M EUR.
When did MindBio Therapeutics complete a stock split?▼
The last stock split for MindBio Therapeutics was on November 06, 2025 with a ratio of 1:400.
Where is MindBio Therapeutics headquartered?▼
MindBio Therapeutics is headquartered in Vancouver, DE.